GlassScriptPhysician profile
Sharla Clark
NPI 1093078578
$2,094.71
in general payments reported to CMS, 2019-2025
33 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $112 · 2021: $360 · 2022: $762 · 2023: $406 · 2024: $63.83 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.63 | 2021-2023 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $339.35 | 2019-2024 | Prolia, Evenity |
| Lilly USA, LLC | $239.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merz North America, INC. | $124.19 | 2023-2025 | Xeomin |
| Novo Nordisk INC | $107.94 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $83.80 | 2019-2023 | Pediarix, Bexsero, Shingrix |
| Allergan, INC. | $64.66 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $49.57 | 2019-2022 | |
| Abbott Laboratories | $46.80 | 2022-2023 | Freestyle Libre 3 |
| Galderma Laboratories, L.P. | $43.82 | 2025 | Dysport |
| Biohaven Pharmaceutical Holding Company LTD. | $43.39 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $39.80 | 2021 | |
| Therapeuticsmd, INC. | $34.17 | 2021-2022 | |
| Boston Scientific Corporation | $31.99 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $29.13 | 2021 | |
| Nevro Corp. | $26.66 | 2020-2021 | |
| Pfizer INC. | $24.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $21.05 | 2025 | |
| Sanofi Pasteur INC. | $19.97 | 2022 | |
| Medtronic, INC. | $17.69 | 2023 | Minimed 770g |
| Xeris Pharmaceuticals, INC. | $17.23 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $15.76 | 2021 | |
| Exact Sciences Corporation | $15.21 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $15.21 | 2024 | Korlym |
| Tandem Diabetes Care, INC. | $15.15 | 2021 | |
| Grifols USA, LLC | $15.00 | 2019 | |
| Dexcom, INC. | $14.96 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $14.92 | 2023 | Veozah |
| Apria Healthcare LLC | $14.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.19 | 2020 | |
| Arbor Pharmaceuticals, INC. | $10.82 | 2019 | |
| Sumitomo Pharma America, INC. | $3.50 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharla Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.